In this study, we investigated the role of peroxisome proliferator-activated receptor γ (PPARγ) on storeoperated calcium entry (SOCE) and expression of the main store-operated calcium channel (SOCCs) components, canonical transient receptor potential (TRPC) in chronic hypoxia (CH)-induced pulmonary hypertension (CHPH) rat models. Small interfering RNA (siRNA) knockdown and adenoviral overexpression strategies were constructed for loss-of-function and gain-of-function experiments. PPARγ agonist rosiglitazone attenuates the pathogenesis of CHPH and suppresses Hif-1α, TRPC1, TRPC6 expression in the distal pulmonary arteries (PA), and SOCE in freshly isolated rat distal pulmonary arterial smooth muscle cells (PASMCs). By comprehensive use of knockdown and overexpression studies, and bioinformatical analysis of the TRPC gene promoter and luciferase reporter assay, we demonstrated that PPARγ exerts roles of anti-proliferation, anti-migration, and proapoptosis in PASMCs, likely by inhibiting the elevated SOCE and TRPC expression. These effects were inhibited under the conditions of hypoxia or Hif-1α accumulation. We also found that under hypoxia, accumulated Hif-1α protein acts as upstream of suppressed PPARγ level; however, targeted PPARγ rescue acts as negative feedback on suppressing Hif-1α level and Hif-1α mediated signaling pathway. PPARγ inhibits CHPH by targeting SOCE and TRPC via inhibiting Hif-1α expression and signaling transduction.
Introduction
Pulmonary hypertension (PH) is a severe and progressive disease accompanied with poor prognosis and high mortality. It is pathologically characterized by excessive pulmonary vascular remodeling, including smooth muscle cell Y Wang, W Lu, and K Yang contributed equally to this work.
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The online version of this article (doi:10.1007/s00109-014-1216-4) contains supplementary material, which is available to authorized users. ] i ) is thought to be a key mediator of both the proliferation and migration [1] [2] [3] . Moreover, the hypoxiaenhanced store-operated calcium entry (SOCE) through storeoperated calcium channels (SOCCs) largely accounts for the elevated [Ca 2+ ] i in PASMCs. In mammalian cells, SOCCs are believed to be composed of transient receptor potential (TRP) proteins [3] [4] [5] . Previous studies demonstrated that chronic hypoxia selectively upregulates the expression of canonical transient receptor potential 1 (TRPC1) and TRPC6 in PASMCs, which are responsible for the triggered SOCE in PASMCs, and ultimately contributes to the pathogenesis of chronic hypoxia-induced pulmonary hypertension (CHPH) [2, 6] .
Hypoxia rapidly induced protein accumulation of hypoxiainducible factor 1α (Hif-1α) and leads to increased expression of genes regulated by the hypoxia-responsive element (HRE) [7] . Functional HIF-1 exists as an α, β heterodimer, the activity of which is dependent on hypoxic induction of the α subunit, as HIF-1β is ubiquitously expressed under normoxic condition, whereas Hif-1α is selectively stabilized under hypoxia, translocates into the nucleus and binds to the HREs (5′-RCGTG-3′), results in the transcriptional induction of multiple gene promoters, and further leads to vascular remodeling, glucose metabolism, and cell proliferation/apoptosis [8] [9] [10] . Accumulating evidence indicates that Hif-1α is involved in the pathophysiology of CHPH. Our previous studies also demonstrated that overexpression of Hif-1α is associated with upregulation of TRPC1 and TRPC6 and the regulation of intracellular calcium homeostasis in PASMCs [11] .
Peroxisome proliferator-activated receptors (PPARs), a kind of ligand-activated nuclear hormone receptor superfamily, are ubiquitously expressed in pulmonary vascular endothelial and smooth muscle cells [12, 13] and are composed of three distinct isoforms: α, β/δ, and γ [14] . Transcriptional activation of the PPARγ receptor requires heterodimerization with the retinoid receptor, retinoid X receptor (RXR) [15] , and then the activated PPARγ/RXR heterodimer binds to PPAR response elements (PPRE) in the promoter region of responsive genes to enhance or reduce the transcription of target genes in a broad variety of tissues [16] . Emerging evidence indicates that loss of PPARγ expression and function may be associated with PH, while stimulating PPARγ may benefit PH. Recent research even confirmed that activation of PPARγ with thiazolidinediones (TZDs) like troglitazone and rosiglitazone (RSG) attenuated PH caused by monocrotaline (MCT) [17] or hypobaric hypoxia [18] in rats. Since both PPARγ and Hif-1α are strongly evidenced associated with PH pathogenesis, the interaction between PPARγ and Hif-1α, however, is still unknown.
In the present study, we detected the role of PPARγ on PH pathogenesis in CHPH animal models and especially determine the role of PPARγ on hypoxia induction of TRPC expression, SOCE, and basal [Ca 2+ ] i in PASMCs. We also examined the molecular mechanisms underlying the transcriptional regulation of TRPC by PPARγ and Hif-1α under hypoxic condition.
Method
Establishment of the rat CHPH model and RSG treatment Adult 6 to 8-week-old wild-type Sprague-Dawley (SD) rats were exposed to chronic hypoxia (10 % O 2 ) or ambient room air for 21 days, with or without intragastric RSG administration (10 mg/kg/day), as previously described [19] . This protocol was in accordance with National Institutes of Health guidelines for use of live animals and was approved by the Animal Care and Use Committee of The first Affiliated Hospital of Guangzhou Medical University.
Primary culture of rat distal PASMCs
Rat PASMCs were isolated and cultured as previously described [2] . The cellular purity of PASMCs in all the experiments was assessed to be >95 %.
Calcium imaging experiment
Calcium imaging experiments were performed as described previously [2] . Fluorescence images of the cells were recorded by a Ratio Vision digital fluorescence microscopy system and analyzed by InCyte software. 
Measurement of apoptosis
Cell apoptosis was determined by the detection of cleavage of caspase-3. Proteins extracted from PASMCs were used to analyze the protein expression of cleaved caspase-3 by using Western blotting.
siRNA silencing
All siRNA duplexes were synthesized by Shanghai GenePharma. Knockdown efficiency was determined by quantitative real-time PCR (qRT-PCR) and Western blotting.
Adenoviral infection
Adenovirus (Ad) constitutively overexpressing active PPARγ, Ad-negative shuttle, and Ad-green fluorescent protein were constructed. PASMCs were infected with the adenoviruses for 6 h and then maintained in serum-free DMEM.
Real-time quantitative PCR
Total RNA was extracted from PASMCs using RNAi Plus Reagent (Takara, Japan). Reverse transcription was performed using iScript cDNA synthesis kit (Takara, Japan). Real-time quantitative PCR (qPCR) was performed using QuantiTect SYBR Green PCR Master Mix (Bio-Rad, Hercules, CA) in real-time PCR detection system (Bio-Rad, Hercules, CA).
Western blot analysis
Distal PA or PASMCs were homogenized in TPER lysis buffer (Pierce, Rockford, IL) containing 5 % protease inhibitor cocktail (Sigma, St. Louis, MO), 1 mM EDTA, and 200 M4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride. Western blotting was conducted with the method as we previously described [11] .
Luciferase reporter assay
A dual reporter gene assay for studying Hif-1α-dependent gene regulation was performed as described by literature [20] ; firefly and Renilla luciferase activity was measured independently in cell extracts with a bioluminometer (Biozym, Oldendorf, Germany).
Statistical analysis
Statistical data are expressed as mean±SEM. When appropriate, t test and one-way ANOVA were applied. In all cases, p<0.05 was considered statistically significant. All experiments were repeated at least three times.
Results

RSG inhibited CHPH pathogenesis and suppressed chronic hypoxia-induced TRPC expression in rats
Consistent with our previous studies [11, 21] , rats exposed to chronic hypoxia (10 % O 2 for 21 days) successfully developed CHPH, featuring as right ventricular systolic pressure (RVSP) increased from 21.64±2.35 mmHg to 50.73±4.98 mmHg and RV mean pressure from 10.85 ± 0.40 mmHg in normoxic control rats to 22.77 ± 0.94 mmHg in hypoxic rats, respectively ( Immunohistochemistry examinations demonstrated that after 21-day chronic hypoxic exposure, the media wall of the distal PA was markedly thickened (Fig. 1e) . RSG obviously relieved the hypoxia-induced PA wall thickening. The ratio of vascular lumen area (2 × medial wall thickness/external diameter) in chronic hypoxic rats (36.4 ± 2.4 %) was statistically greater than that in normoxic controls (15.1±3.5 %, p<0.01), and the ratio in hypoxia+RSG rats drop to 27.9±4.7 % (p<0.05 vs. hypoxic control rats). In parallel, our data showed a marked decrease in PPARγ and increase in TRPC1 and TRPC6 protein expression in the isolated rat distal PA from the chronic hypoxic group, which was attenuated by RSG ( Fig. 1f-i) .
PPARγ exerted roles of anti-proliferation, anti-migration, and pro-apoptosis in hypoxic PASMCs Hypoxia enhances PASM Cs proliferation [ 10] . Accumulating evidence implicated that PPARγ activation elicits anti-proliferative, pro-apoptotic, and vasodilatory effects [17, 18] . We found that GW1929, a highly potent PPARγ agonist, attenuated hypoxia-induced proliferation in a dose-and time-dependent manner (Online Figure 2) . To confirm these results, siRNA targeting PPARγ (siR-PPARγ) and adenovirus harboring PPARγ (Ad-PPARγ) were synthesized/constructed to knockdown or overexpress PPARγ in PASMCs, respectively. Non-targeting control siRNA (siR-NC) was used as a negative control for siPPARγ and Ad-Shuttle served as a mock-vehicle control for Ad-PPARγ. As seen in Fig. 2a , b, prolonged hypoxia (4 % O 2 , 60 h)-enhanced proliferation was aggravated by siR-PPARγ treatment, in contrast, attenuated by Ad-PPARγ treatment. Likewise, similar effects existed in the migration assay (Fig. 2c, d ) and measurement of apoptosis, as reflected by the expression level of cleaved caspase-3, which is well recognized as a key element in the signal cascade leading to apoptosis (Fig. 2e, f Fig. 3a, b ), but not in normoxic cells (34±1.5 % in Nor+siR-PPARγ group vs. 33±3.7 % in Nor+siR-NC control, p=0.89), whereas Ad-PPARγ infection decreased the Mn 2+ quenching rate to 42±4.1 % in hypoxic cells (p<0.05 vs. 55±2.64 % Hy+Ad-Shuttle control; Fig. 3c, d ), but not in normoxic cells. As shown in Fig. 3e , f, PASMCs exposed to prolonged hypoxia showed significantly higher resting [Ca 2+ ] i level (Fig. 3e, 
PPARγ inhibited hypoxia-upregulated TRPC expression in PASMCs
Similar to the previous finding [22] , our results showed similar pattern of hypoxia-increased TRPC1 and TRPC6 and hypoxia-decreased PPARγ messenger RNA (mRNA) level (Fig. 4a, b ), as well as protein level (Fig. 4c, d ). Transfection with siR-PPARγ (25 nM) significantly aggravated hypoxiaincreased mRNA and protein of TRPC1 and TRPC6 (Fig. 4a,  c, e) . On the other side, Ad-PPARγ remarkably decreased both mRNA and protein level of TRPC1 and TRPC6 under hypoxic condition, but not under normoxic condition (Fig. 4b,  d , f).
Effects of PPARγ on hypoxic activation of TRPC1/TRPC6 promoter activity
To further determine whether PPARγ could regulate hypoxia-triggered TRPC1 and TRPC6 promoter activity, potential homologous transcription factor binding sites in the TRPC1 and TRPC6 promoter were assessed (Online Figure 3) , and we constructed the reporter plasmids for TRPC1 and TRPC6 promoters. The effects of hypoxia and PPARγ on TRPC1 and TRPC6 promoter activity was then measured by transfecting these reporter constructs into cultured PASMCs for luciferase reporter assay. As demonstrated in Fig. 5a , b, hypoxic exposure significantly enhanced the promoter activity of TRPC1 and TRPC6 (Fig. 5a, b) . Since that hypoxia elevated the Hif-1α accumulation and triggered the expression of hypoxiaresponsive element (HRE)-targeted genes, the upregulation of TRPC may be stimulated by Hif-1α. We then treated the cells with GW1929 during the last 24 h of hypoxia exposure and found that the enhanced promoter activity of TRPC1 (Fig. 5b, 0. 1928±0.0230 vs. hypoxia control, p < 0.05), especially TRPC6 (Fig. 5a , 0.1570 ± 0.0316 vs. hypoxia control, p<0.05), was significantly recovered. On the contrary, inhibition of PPARγ with antagonist T0070907 stimulated hypoxia-driven TRPC promoter activity. These results collectively suggested a recovery effect of PPARγ on hypoxia-induced activation of TRPC6 and TRPC1 promoter.
PPARγ downregulated Hif-1α expression in PASMCs
Previous evidence indicated that Hif-1α might act as a positive regulator of hypoxic induction of TRPC expression and function in upstream of TRPC proteins [11] . To explore whether PPARγ affects Hif-1α expression, primary cultured rat distal PASMCs were transfected with siR-PPARγ. As seen in Fig. 6 , prolonged hypoxia increased Hif-1α mRNA expression for 32 % and increased protein expression for 153.5 %. Transfection with siR-PPARγ significantly aggravated hypoxic increases in Hif-1α mRNA (Fig. 6a, 123 .9± 0.068 % vs. hypoxia siR-NC, p<0.05) and protein (Fig. 6c, 
Hif-1α downregulated PPARγ expression in PASMCs
As PPARγ and Hif-1α are known to both locate in nucleus and can regulate targeted gene expression at transcription level, combined with the aforementioned results, 
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Fold to control we further examined the effect of Hif-1α on PPARγ using siR-Hif-1α and Ad-Hif-1α. PASMCs were exposed to prolonged hypoxia (4 % O 2 , 60 h) with or without siRHif-1α or Ad-Hif-1α treatment. As shown in Fig. 7 , Hif-1α expression was upregulated in hypoxia-exposed PASMCs as expected. PPARγ expression was suppressed by Ad-Hif-1α infection (Fig. 7b, 33 .1±0.041 % vs. hypoxia siR-NC, p<0.05; Fig. 7e , f, 64.9±0.063 % vs. hypoxia siR-NC, p<0.05) and promoted by siR-Hif-1α transfection in mRNA (Fig. 7a, 129 .6±0.093 % vs. hypoxia siR-NC, p<0.05) and protein (Fig. 7c, d , 150.6±0.063 % vs. hypoxia siR-NC, p<0.05) levels, which indicates a mutual regulation between PPARγ and Hif-1α convincingly.
Hif-1α and PPARγ shared mutual inhibition mechanism
Since Hif-1α and PPARγ inhibited the expression of each other, suggesting a potential mutual inhibition mechanism, we sought to further confirm this hypothesis by more direct evidence. To elucidate this question, firstly, we applied treatment of cobalt chloride (CoCl 2 ), a wellknown hypoxia mimetic agent, to rapidly accumulate Hif-1α protein in normoxic PASMCs. As we expected, CoCl 2 promoted Hif-1α and TRPC expression drastically and inhibited PPARγ inversely (Fig. 8a, b) . Then, combination of ad-PPAR and siR-Hif-1α treatments was performed to measure the signaling transduction activity on TRPC expression. As shown in Fig 8c, d , Hif-1α expression was induced in hypoxic PASMCs and attenuated by either siR-Hif-1α transfection or Ad-PPARγ infection, extremely downregulated by treatment of Ad-PPARγ plus siR-Hif-1α. PPARγ expression is suppressed significantly under hypoxia and promoted by siR-Hif-1α transfection or Ad-PPARγ infection, and this enhancement also displayed after combination treatment of Ad-PPARγ and siR-Hif-1α. Similarly, TRPC expression followed the same tendency as Hif-1α expression, whereas its comparative expression in Ad-PPARγ solely and combination treatment of Ad-PPARγ and siR-Hif-1α indicated that HIF-1 is the upstream of PPARγ and further regulate TRPC expression.
Hif-1α acted upstream of PPARγ in hypoxic PASMCs
To further detect that between Hif-1α and PPARγ, which one acts as an upstream factor to regulate the other one in hypoxic PASMCs, the expression dynamics of the two factors within 12 h of hypoxic exposure were then examined. Data showed that the expression of Hif-1α was slightly increased 126.6± 0.130 % at 0.5 h of hypoxic exposure, significantly elevated 148.7±0.077 % at 2 h and reached a peak at 4 h (171.1 ± 0.073 %), started declining at 8 h, and remained detectable until 12 h of hypoxic exposure (Fig. 8e, f) . On the other hand, the expression of PPARγ was sharply reduced 52.4±0.09 % at just 0.5 h of hypoxic exposure, then recovered weakly until 4 h (80.8±0.047 %), and next declined until 12 h of hypoxic exposure (47.7 ± 0.010 %) (Fig. 8e, f) . These results indicated that hypoxia rapidly leads to Hif-1α increase and results in PPARγ suppression.
Discussion
The present study demonstrated that RSG attenuated the characteristics of CHPH likely through recovering hypoxiadownregulated PPARγ to the following: (1) inhibited hypoxia-increased expression of TRPC1 and TRPC6; (2) attenuated hypoxia-triggered SOCE and basal [Ca 2+ ] i ; and (3) inhibited hypoxia-elevated proliferation and migration, and reversed hypoxia-inhibited apoptosis in PASMCs. In addition, we also provided fundamental mechanistic evidence to demonstrate for the first time that targeted rescue of PPARγ could negatively inhibit Hif-1α level and reverse hypoxiaupregulated TRPC expression and hypoxia-elevated SOCE in hypoxic PASMCs.
Currently, the group of specific PPARγ agonists, like RSG, has been proved by several studies to be beneficial in the treatment of PH. By obtaining decreased RVSP and media wall thickening of small pulmonary vasculature in CHPH and MCT-PH models, we confirmed that RSG could markedly attenuate the elevated RVSP in both of the models, which are in line with previous reports [17, 18] . However, we also surprisingly saw an unaltered Fulton index after RSG treatment, which indicated no obvious effect on right ventricle hypotrophy (RVH). There are several potential explanations regarding to this phenomenon: (1) The decrease in RVSP could be attributed to a decompensated RV, as we would predict that RVSP would fall in a decompensated heart; (2) the decrease in RVSP could be caused by a decrease in afterload and is not a consequence of heart fail; and (3) RSG treatment may have beneficial effects on the pulmonary vasculature in PH, but no obvious or even negative effects on the heart, which have been previously reported in the Fold to control
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Fold to control diabetic models [23] . Due to the lack of the data representing the cardiac output and the mean pulmonary arterial pressure, which of these potential explanations are correct remains unclear. To figure out, this question will be one of our main goals in the future study. Previous publication indicated that PPARγ ligands play essential roles in impairing endothelial function and attenuating the development of atherosclerotic lesions in apolipoprotein E (ApoE) or LDL receptor-deficient mouse atherosclerosis models [24, 25] . PPARγ also suppresses the expression and activity of NADPH oxidase through downregulating Nox4 [26] , inhibits heightened PDGF signaling [27] [28] [29] , and reduces TGF-β1-induced extracellular matrix molecule synthesis and growth factor secretion [30] . We and others have previously demonstrated that increased intracellular-free Ca 2+ concentration in PASMCs is a major trigger for pulmonary vasoconstriction and an important stimulus for PASMC proliferation and migration [31] . Exposure to chronic hypoxia caused enhanced activity of SOCCs other than VDCCs [32] . As a consequence, chronic hypoxia not only elevated and maintained increased resting [Ca 2+ ] i and active tone but also upregulated expression of the main SOCCs components, TRPC1 and TRPC6 [11] . We then further examined the effect of RSG on hypoxia-upregulated TRPC1 and TRPC6 expression in distal PAs and PASMCs. Notably, RSG inhibited hypoxic increases of TRPC1 and TRPC6.
To further explore the role of PPARγ in regulating Ca 2+ homeostasis and functional consequences in PASMCs, we adopted and constructed high potent PPARγ agonist GW1929, specific siRNA targeting PPARγ, and recombinant adenovirus harboring PPARγ gene for the following study. All these approaches suggest a protective role of PPARγ on TRPC1/6 expression, SOCE, basal Ca 2+ concentration, proliferation, and migration in PASMCs. Convincingly, the physiological and pathophysiological benefits of RSG to PH were associated with parallel molecular and functional changes.
To detect how TRPC expression is regulated in transcriptional level by hypoxia, we further analyzed the DNA sequence of TRPC promoter region and strikingly identify PPRE and HRE within the regulatory regions of TRPC gene promoter. By using luciferase assay, PPARγ agonist GW1929 significantly suppressed TRPC transactivation in PASMCs under hypoxia. On the contrary, inhibition of PPARγ with antagonist T0070907 aggravated hypoxia-driven TRPC promoter activity. All differences took place under hypoxia condition rather than normoxia. These results suggested that PPARγ acts indirectly on the TRPC transcription regulation and might be through influencing Hif-1α transactivity. This hypothesis was then proved by the inhibition role of PPARγ on Hif-1α expression on both mRNA and protein levels. The diversity of regulatory mechanism occurs between PPARγ and Hif-1α in various studies. On one hand, Hif-1α can repress PPARγ by HIF-1-regulated gene DEC1/Stra13 under hypoxia in adipocyte differentiation [33] . In response to pathologic stress of cardiac metabolism, Hif-1α directly activates PPARγ transcription, and PPARγ is a key downstream effector of Hif-1α-driven TAG accumulation and apoptosis in cardiomyocytes [34] . On the other hand, PPARγ shifts to the upstream of Hif-1α. For example, PPARγ modulates reactive oxygen species generation and activation of NF-κB and Hif-1α in allergic airway disease of mice [35] . Additionally, PPARγ agonist 15d-PGJ2 induced stabilization and accumulation of Hif-1α in nuclear, without affecting Hif-1α mRNA levels or proteasome activity in human kidney HK-2 cells [36] . Alternatively, whether Hif-1α interacting with PPARγ precedes TRPC promoter involvement remains an area of active investigation in our laboratories. In this event, we supposed that Hif-1α may bind to HRE sites in PPARγ promoter area, physically preventing PPARγ from binding to adjacent sites and thereby inhibiting TRPC promoter activity. To elucidate this issue, we applied CoCl 2 in PASMCs under normoxia for independence of the effects of global hypoxia. The results confirmed that the direct activation of HIF-1α results in decreased PPARγ expression and increased expression in TRPC1 and TRPC6. Furthermore, combination treatment of ad-PPAR and siR-Hif-1α verified this conclusion convincingly. Finally, the expression dynamic of PPARγ and Hif-1α under hypoxic condition was also examined. Data showed that when Hif-1α reached a peak, PPARγ subsequently descend, suggesting that Hif-1α expression is more sensitive than PPARγ in response to hypoxia during 24 h. As a summary, we concluded that PPARγ and Hif-1α play mutual antagonistic role in regulating TRPC transcription under hypoxic exposure.
Collectively, an outline was summarized as shown in Fig. 8g . Hypoxia exposure led to Hif-1α accumulation, which enhanced SOCE through activating TRPC expression. As a consequence of hypoxic exposure, the balance between Hif-1α and PPARγ signaling becomes dysregulated, resulting in promoted proliferation and migration in Fig. 7 Hif-1α promoted prolonged hypoxia-induced TRPC expression in PASMCs from normoxic rats and downregulate PPARγ expression. PASMCs isolated from normoxic rats were treated with prolonged hypoxia (4 % O 2 , 60 h) with or without siR-Hif-1α or Ad-Hif-1α. The relative mRNA levels (to 18 s) for PPARγ and Hif-1α were determined by quantitative RT-PCR, and the results were shown as percentage to that of normoxia in a, b. The protein levels of PPARγ and Hif-1α were measured by Western blotting (c, e), and their band intensity was normalized to that of β-actin (d, f). Data were presented as means± SEM, n=4 in each group. *p<0.05 versus respective normoxic control; **p<0.01 versus respective hypoxic control However, recovered PPARγ activity by specific agonist (like RSG) then challenges the Hif-1α-mediated signaling (such as TRPC induction) by directly suppressing Hif-1α expression, which subsequently prevents the PH pathogenesis. To our knowledge, it is the first report that PPARγ may regulate TRPC expression through inhibiting Hif-1α signaling. Our results provide new insights into molecular mechanism basis to explain how PPARγ inhibits TRPC and intracellular calcium homeostasis in PASMCs, which might be valuable in identifying novel targets to improve the treatment of patients with PH.
